S Shackelford Pharma

WIPO WIPO 2021

Protect this trademark from copycats!

With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.

The International trademark S Shackelford Pharma was filed as Figurative mark on 09/13/2021 at the World Intellectual Property Organization.

Search on Amazon
Logodesign (Wiener Klassifikation)

#Crosses #Other geometrical figures, indefinable designs #Letters presenting a special form of writing #Greek cross, St. Andrew's cross #Letters linked to a figurative element #Series of letters presenting different forms of writing #Series of letters in different dimensions

Trademark Details Last update: June 12, 2023

Trademark form Figurative mark
File reference 1674567
Countries Australia em India Japan
Base trademark CA No. 2098683, April 9, 2021
Application date September 13, 2021
Expiration date September 13, 2031

Trademark owner

Shackelford Pharma Inc.
1000-355 Burrard St
Vancouver BC V6C 2G8
CA

Trademark representatives

VANTEK INTELLECTUAL PROPERTY LLP (AKA D/B/A VANTEK IP LLP)
101 - 1001 West Broadway, Suite 380 CA

goods and services

05 Medicinal compounds containing cannabis, cannabis derivatives, natural cannabinoids, or synthetic cannabinoids; medicinal compounds containing cannabis, cannabis derivatives, natural cannabinoids, or synthetic cannabinoids for treating headaches, neurodegeneration, neurogenesis, epilepsy, childhood epilepsy, paediatric encephalopathies, pain, cancer, managing the effects of chemotherapy, Tourette Syndrome, post-traumatic stress disorder (PTSD), nausea, vomiting, premenstrual syndrome (PMS), neurologic conditions, sleep disorders, cognitive decline, facial pain, spasms, gastrointestinal diseases, rare diseases, Alzheimer's disease, appetite loss, cancer, Crohn's disease, anorexia, bulimia, epilepsy, glaucoma, schizophrenia, multiple sclerosis, muscle spasms, nausea, pain, headaches, wasting syndrome (cachexia), and diseases classified as "orphan" by the US Food and Drug Administration, namely, medicinal compounds containing cannabis, cannabis derivatives, natural cannabinoids, or synthetic cannabinoids for treating diseases and medical conditions classified as "orphan" by the US food and drug administration, namely, Lennox-Gastaut Syndrome, Dravet Syndrome, CDKL5, 15q Duplication Syndrome, KCNQ2 related epileptic encephalopathy, SCN8A related epileptic encephalopathy, Electrical status epilepticus in sleep (ESES), Landau-Kleffner syndrome, Continuous spikes and waves during sleep, Tuberous sclerosis complex, Doose Syndrome, Otahara Syndrome, Rett Syndrome, West Syndrome, SYNGAP related epileptic encephalopathy, Fragile X Syndrome, epilepsy with focal cortical dysplasia type II, KCNT1 related epileptic encephalopathy, SCN2A related epileptic encephalopathy, STXBP1 related epileptic encephalopathy, KAND KIF1A related epileptic encephalopathy, HNRNPH2 related epileptic encephalopathy, Phelan-McDermid Syndrome - SHANK3, Angelman Syndrome, Established Status Epilepticus, Refractory Status Epilepticus, Juvenile Myoclonic Epilepsy/Janz Syndrome, Catamenial epilepsy, Drug resistant mesial temporal lobe epilepsy, Occipital Lobe epilepsy, Jeavons syndrome, Benign Rolandic epilepsy or benign childhood epilepsy with centrotemporal spikes (BCECTS), Epilepsy with myoclonic absences, Childhood absence epilepsy (CAE), Tuberous Sclerosis/Tuberous Sclerosis Complex (TSC), Panayiotopoulos syndrome, Benign Occipital Epilepsy, Idiopathic childhood occipital epilepsy of Gastaut (ICOE-G), Benign myoclonic epilepsy in infancy, Myoclonic astatic epilepsy (MAE), Cornelia de Lange Syndrome (CdLS), Convulsive Seizures, TBI Seizures, Focal Seizures, Generalized onset Seizures, Progressive Myoclonic Epilepsy, Reflex Epilepsy, Abdominal Epilepsy, Photosensitive Epilepsy, Refractory Epilepsy, Automatism Epilepsy, Catamenial epilepsy, Epilepsia partialis continua, Febrile infection-related epilepsy syndrome (FIRES), Migralepsy, Musicogenic epilepsy, Nocturnal Frontal Lobe epilepsy, Occipital Lobe epilepsy, Post-traumatic (TBI) epilepsy (PTE), Temporal lobe epilepsy (TLE), Unverricht-Lundborg disease (abbreviated ULD or EPM1), Vertiginous epilepsy; Medicinal herbal extracts for treating disease; Medicinal herbal extracts for treating headaches, neurodegeneration, neurogenesis, epilepsy, childhood epilepsy, paediatric encephalopathies, pain, cancer, managing the effects of chemotherapy, Tourette Syndrome, post-traumatic stress disorder (PTSD), nausea, vomiting, premenstrual syndrome (PMS), neurologic conditions, sleep disorders, cognitive decline, facial pain, spasms, gastrointestinal diseases, rare diseases, Alzheimer's disease, appetite loss, cancer, Crohn's disease, anorexia, bulimia, epilepsy, glaucoma, schizophrenia, multiple sclerosis, muscle spasms, nausea, pain, headaches, wasting syndrome (cachexia), and diseases classified as "orphan" by the US Food and Drug Administration, namely, medical cannabis and marijuana extracts for treating diseases and medical conditions classified as "orphan" by the US food and drug administration, namely, Lennox-Gastaut Syndrome, Dravet Syndrome, CDKL5,15q Duplication Syndrome, KCNQ2 related epileptic encephalopathy, SCN8A related epileptic encephalopathy, Electrical status epilepticus in sleep (ESES), Landau-Kleffner syndrome, Continuous spikes and waves during sleep, Tuberous sclerosis complex, Doose Syndrome, Otahara Syndrome, Rett Syndrome, West Syndrome, SYNGAP related epileptic encephalopathy, Fragile X Syndrome, epilepsy with focal cortical dysplasia type II, KCNT1 related epileptic encephalopathy, SCN2A related epileptic encephalopathy, STXBP1 related epileptic encephalopathy, KAND KIF1A related epileptic encephalopathy, HNRNPH2 related epileptic encephalopathy, Phelan-McDermid Syndrome - SHANK3, Angelman Syndrome, Established Status Epilepticus, Refractory Status Epilepticus, Juvenile Myoclonic Epilepsy/Janz Syndrome, Catamenial epilepsy, Drug resistant mesial temporal lobe epilepsy, Occipital Lobe epilepsy, Jeavons syndrome, Benign Rolandic epilepsy or benign childhood epilepsy with centrotemporal spikes (BCECTS), Epilepsy with myoclonic absences, Childhood absence epilepsy (CAE), Tuberous Sclerosis/Tuberous Sclerosis Complex (TSC), Panayiotopoulos syndrome, Benign Occipital Epilepsy, Idiopathic childhood occipital epilepsy of Gastaut (ICOE-G), Benign myoclonic epilepsy in infancy, Myoclonic astatic epilepsy (MAE), Cornelia de Lange Syndrome (CdLS), Convulsive Seizures, TBI Seizures, Focal Seizures, Generalized onset Seizures, Progressive Myoclonic Epilepsy, Reflex Epilepsy, Abdominal Epilepsy, Photosensitive Epilepsy, Refractory Epilepsy, Automatism Epilepsy, Catamenial epilepsy, Epilepsia partialis continua, Febrile infection-related epilepsy syndrome (FIRES), Migralepsy, Musicogenic epilepsy, Nocturnal Frontal Lobe epilepsy, Occipital Lobe epilepsy, Post-traumatic (TBI) epilepsy (PTE), Temporal lobe epilepsy (TLE), Unverricht-Lundborg disease (abbreviated ULD or EPM1), Vertiginous epilepsy; medicinal herbal preparations; medicinal herbal preparations for treating headaches, neurodegeneration, neurogenesis, epilepsy, childhood epilepsy, paediatric encephalopathies, pain, cancer, managing the effects of chemotherapy, Tourette Syndrome, post-traumatic stress disorder (PTSD), nausea, vomiting, premenstrual syndrome (PMS), neurologic conditions, sleep disorders, cognitive decline, facial pain, spasms, gastrointestinal diseases, rare diseases, Alzheimer's disease, appetite loss, cancer, Crohn's disease, anorexia, bulimia, epilepsy, glaucoma, schizophrenia, multiple sclerosis, muscle spasms, nausea, pain, headaches, wasting syndrome (cachexia), and diseases classified as "orphan" by the US Food and Drug Administration, namely marijuana preparations, cannabis dried flowers and concentrates for treating diseases and medical conditions classified as "orphan" by the US food and drug administration, namely, Lennox-Gastaut Syndrome, Dravet Syndrome, CDKL5, 15q Duplication Syndrome, KCNQ2 related epileptic encephalopathy, SCN8A related epileptic encephalopathy, Electrical status epilepticus in sleep (ESES), Landau-Kleffner syndrome, Continuous spikes and waves during sleep, Tuberous sclerosis complex, Doose Syndrome, Otahara Syndrome, Rett Syndrome, West Syndrome, SYNGAP related epileptic encephalopathy, Fragile X Syndrome, epilepsy with focal cortical dysplasia type II, KCNT1 related epileptic encephalopathy, SCN2A related epileptic encephalopathy, STXBP1 related epileptic encephalopathy, KAND KIF1A related epileptic encephalopathy, HNRNPH2 related epileptic encephalopathy, Phelan-McDermid Syndrome - SHANK3, Angelman Syndrome, Established Status Epilepticus, Refractory Status Epilepticus, Juvenile Myoclonic Epilepsy/Janz Syndrome, Catamenial epilepsy, Drug resistant mesial temporal lobe epilepsy, Occipital Lobe epilepsy, Jeavons syndrome, Benign Rolandic epilepsy or benign childhood epilepsy with centrotemporal spikes (BCECTS), Epilepsy with myoclonic absences, Childhood absence epilepsy (CAE), Tuberous Sclerosis/Tuberous Sclerosis Complex (TSC), Panayiotopoulos syndrome, Benign Occipital Epilepsy, Idiopathic childhood occipital epilepsy of Gastaut (ICOE-G), Benign myoclonic epilepsy in infancy, Myoclonic astatic epilepsy (MAE), Cornelia de Lange Syndrome (CdLS), Convulsive Seizures, TBI Seizures, Focal Seizures, Generalized onset Seizures, Progressive Myoclonic Epilepsy, Reflex Epilepsy, Abdominal Epilepsy, Photosensitive Epilepsy, Refractory Epilepsy, Automatism Epilepsy, Catamenial epilepsy, Epilepsia partialis continua, Febrile infection-related epilepsy syndrome (FIRES), Migralepsy, Musicogenic epilepsy, Nocturnal Frontal Lobe epilepsy, Occipital Lobe epilepsy, Post-traumatic (TBI) epilepsy (PTE), Temporal lobe epilepsy (TLE), Unverricht-Lundborg disease (abbreviated ULD or EPM1), Vertiginous epilepsy; Marijuana derivatives, natural cannabinoids, and synthetic cannabinoids used for treating medical conditions; Marijuana derivatives, natural cannabinoids, and synthetic cannabinoids used for treating headaches, neurodegeneration, neurogenesis, epilepsy, childhood epilepsy, paediatric encephalopathies, pain, cancer, managing the effects of chemotherapy, Tourette Syndrome, post-traumatic stress disorder (PTSD), nausea, vomiting, premenstrual syndrome (PMS), neurologic conditions, sleep disorders, cognitive decline, facial pain, spasms, gastrointestinal diseases, rare diseases, Alzheimer's disease, appetite loss, cancer, managing the effects of chemotherapy, Crohn's disease, anorexia, bulimia, epilepsy, glaucoma, schizophrenia, multiple sclerosis, muscle spasms, nausea, pain, headaches, wasting syndrome (cachexia), and diseases classified as "orphan" by the US Food and Drug Administration, namely liquids, oils, oral sprays, pills, capsules, creams, tinctures, lotions, suppositories, and baked medicinal goods for treating diseases and medical conditions classified as "orphan" by the US food and drug administration, namely, Lennox-Gastaut Syndrome, Dravet Syndrome, CDKL5,15q Duplication Syndrome, KCNQ2 related epileptic encephalopathy, SCN8A related epileptic encephalopathy, Electrical status epilepticus in sleep (ESES), Landau-Kleffner syndrome, Continuous spikes and waves during sleep, Tuberous sclerosis complex, Doose Syndrome, Otahara Syndrome, Rett Syndrome, West Syndrome, SYNGAP related epileptic encephalopathy, Fragile X Syndrome, epilepsy with focal cortical dysplasia type II, KCNT1 related epileptic encephalopathy, SCN2A related epileptic encephalopathy, STXBP1 related epileptic encephalopathy, KAND KIF1A related epileptic encephalopathy, HNRNPH2 related epileptic encephalopathy, Phelan-McDermid Syndrome - SHANK3, Angelman Syndrome, Established Status Epilepticus, Refractory Status Epilepticus, Juvenile Myoclonic Epilepsy/Janz Syndrome, Catamenial epilepsy, Drug resistant mesial temporal lobe epilepsy, Occipital Lobe epilepsy, Jeavons syndrome, Benign Rolandic epilepsy or benign childhood epilepsy with centrotemporal spikes (BCECTS), Epilepsy with myoclonic absences, Childhood absence epilepsy (CAE), Tuberous Sclerosis/Tuberous Sclerosis Complex (TSC), Panayiotopoulos syndrome, Benign Occipital Epilepsy, Idiopathic childhood occipital epilepsy of Gastaut (ICOE-G), Benign myoclonic epilepsy in infancy, Myoclonic astatic epilepsy (MAE), Cornelia de Lange Syndrome (CdLS), Convulsive Seizures, TBI Seizures, Focal Seizures, Generalized onset Seizures, Progressive Myoclonic Epilepsy, Reflex Epilepsy, Abdominal Epilepsy, Photosensitive Epilepsy, Refractory Epilepsy, Automatism Epilepsy, Catamenial epilepsy, Epilepsia partialis continua, Febrile infection-related epilepsy syndrome (FIRES), Migralepsy, Musicogenic epilepsy, Nocturnal Frontal Lobe epilepsy, Occipital Lobe epilepsy, Post-traumatic (TBI) epilepsy (PTE), Temporal lobe epilepsy (TLE), Unverricht-Lundborg disease (abbreviated ULD or EPM1), Vertiginous epilepsy; medicinal herbs for treating headaches, neurodegeneration, neurogenesis, epilepsy, childhood epilepsy, paediatric encephalopathies, pain, cancer, managing the effects of chemotherapy, Tourette Syndrome, post-traumatic stress disorder (PTSD), nausea, vomiting, premenstrual syndrome (PMS), neurologic conditions, sleep disorders, cognitive decline, facial pain, spasms, gastrointestinal diseases, rare diseases, Alzheimer's disease, appetite loss, cancer, Crohn's disease, anorexia, bulimia, epilepsy, glaucoma, schizophrenia, multiple sclerosis, muscle spasms, nausea, pain, headaches, wasting syndrome (cachexia), and diseases classified as "orphan" by the US Food and Drug Administration, namely Lennox-Gastaut Syndrome, Dravet Syndrome, CDKL5,15q Duplication Syndrome, KCNQ2 related epileptic encephalopathy, SCN8A related epileptic encephalopathy, Electrical status epilepticus in sleep (ESES), Landau-Kleffner syndrome, Continuous spikes and waves during sleep, Tuberous sclerosis complex, Doose Syndrome, Otahara Syndrome, Rett Syndrome, West Syndrome, SYNGAP related epileptic encephalopathy, Fragile X Syndrome, epilepsy with focal cortical dysplasia type II, KCNT1 related epileptic encephalopathy, SCN2A related epileptic encephalopathy, STXBP1 related epileptic encephalopathy, KAND KIF1A related epileptic encephalopathy, HNRNPH2 related epileptic encephalopathy, Phelan-McDermid Syndrome - SHANK3, Angelman Syndrome, Established Status Epilepticus, Refractory Status Epilepticus, Juvenile Myoclonic Epilepsy/Janz Syndrome, Catamenial epilepsy, Drug resistant mesial temporal lobe epilepsy, Occipital Lobe epilepsy, Jeavons syndrome, Benign Rolandic epilepsy or benign childhood epilepsy with centrotemporal spikes (BCECTS), Epilepsy with myoclonic absences, Childhood absence epilepsy (CAE), Tuberous Sclerosis/Tuberous Sclerosis Complex (TSC), Panayiotopoulos syndrome, Benign Occipital Epilepsy, Idiopathic childhood occipital epilepsy of Gastaut (ICOE-G), Benign myoclonic epilepsy in infancy, Myoclonic astatic epilepsy (MAE), Cornelia de Lange Syndrome (CdLS), Convulsive Seizures, TBI Seizures, Focal Seizures, Generalized onset Seizures, Progressive Myoclonic Epilepsy, Reflex Epilepsy, Abdominal Epilepsy, Photosensitive Epilepsy, Refractory Epilepsy, Automatism Epilepsy, Catamenial epilepsy, Epilepsia partialis continua, Febrile infection-related epilepsy syndrome (FIRES), Migralepsy, Musicogenic epilepsy, Nocturnal Frontal Lobe epilepsy, Occipital Lobe epilepsy, Post-traumatic (TBI) epilepsy (PTE), Temporal lobe epilepsy (TLE), Unverricht-Lundborg disease (abbreviated ULD or EPM1), Vertiginous epilepsy; medicinal herbs in dried or preserved form for treating headaches, neurodegeneration, neurogenesis, epilepsy, childhood epilepsy, paediatric encephalopathies, pain, cancer, managing the effects of chemotherapy, Tourette Syndrome, post-traumatic stress disorder (PTSD), nausea, vomiting, premenstrual syndrome (PMS), neurologic conditions, sleep disorders, cognitive decline, facial pain, spasms, gastrointestinal diseases, rare diseases, Alzheimer's disease, appetite loss, cancer, Crohn's disease, anorexia, bulimia, epilepsy, glaucoma, schizophrenia, multiple sclerosis, muscle spasms, nausea, pain, headaches, wasting syndrome (cachexia), and diseases classified as "orphan" by the US Food and Drug Administration, namely medical marijuana and cannabis for treating diseases and medical conditions classified as "orphan" by the US food and drug administration, namely, Lennox-Gastaut Syndrome, Dravet Syndrome, CDKL5,15q Duplication Syndrome, KCNQ2 related epileptic encephalopathy, SCN8A related epileptic encephalopathy, Electrical status epilepticus in sleep (ESES), Landau-Kleffner syndrome, Continuous spikes and waves during sleep, Tuberous sclerosis complex, Doose Syndrome, Otahara Syndrome, Rett Syndrome, West Syndrome, SYNGAP related epileptic encephalopathy, Fragile X Syndrome, epilepsy with focal cortical dysplasia type II, KCNT1 related epileptic encephalopathy, SCN2A related epileptic encephalopathy, STXBP1 related epileptic encephalopathy, KAND KIF1A related epileptic encephalopathy, HNRNPH2 related epileptic encephalopathy, Phelan-McDermid Syndrome - SHANK3, Angelman Syndrome, Established Status Epilepticus, Refractory Status Epilepticus, Juvenile Myoclonic Epilepsy/Janz Syndrome, Catamenial epilepsy, Drug resistant mesial temporal lobe epilepsy, Occipital Lobe epilepsy, Jeavons syndrome, Benign Rolandic epilepsy or benign childhood epilepsy with centrotemporal spikes (BCECTS), Epilepsy with myoclonic absences, Childhood absence epilepsy (CAE), Tuberous Sclerosis/Tuberous Sclerosis Complex (TSC), Panayiotopoulos syndrome, Benign Occipital Epilepsy, Idiopathic childhood occipital epilepsy of Gastaut (ICOE-G), Benign myoclonic epilepsy in infancy, Myoclonic astatic epilepsy (MAE), Cornelia de Lange Syndrome (CdLS), Convulsive Seizures, TBI Seizures, Focal Seizures, Generalized onset Seizures, Progressive Myoclonic Epilepsy, Reflex Epilepsy, Abdominal Epilepsy, Photosensitive Epilepsy, Refractory Epilepsy, Automatism Epilepsy, Catamenial epilepsy, Epilepsia partialis continua, Febrile infection-related epilepsy syndrome (FIRES), Migralepsy, Musicogenic epilepsy, Nocturnal Frontal Lobe epilepsy, Occipital Lobe epilepsy, Post-traumatic (TBI) epilepsy (PTE), Temporal lobe epilepsy (TLE), Unverricht-Lundborg disease (abbreviated ULD or EPM1), Vertiginous epilepsy; pills, capsules, infused with cannabis, medical marijuana, natural cannabinoids, or synthetic cannabinoids; extracts and derivatives of cannabis, medical marijuana, natural cannabinoids, and synthetic cannabinoids for treating headaches, neurodegeneration, neurogenesis, epilepsy, childhood epilepsy, paediatric encephalopathies, pain, cancer, managing the effects of chemotherapy, Tourette Syndrome, post-traumatic stress disorder (PTSD), nausea, vomiting, premenstrual syndrome (PMS), neurologic conditions, sleep disorders, cognitive decline, facial pain, spasms, gastrointestinal diseases, rare diseases, Alzheimer's disease, appetite loss, cancer, Crohn's disease, anorexia, bulimia, epilepsy, glaucoma, schizophrenia, multiple sclerosis, muscle spasms, nausea, pain, headaches, wasting syndrome (cachexia), and diseases classified as "orphan" by the US Food and Drug Administration, namely, salves, concentrates, pastes, extracts, tinctures, marijuana clones, cannabis clones, tissue cultures, powders, juice, resins, oils, and tetrahydrocannabinol (THC) for treating diseases and medical conditions classified as "orphan" by the US food and drug administration, namely, Lennox-Gastaut Syndrome, Dravet Syndrome, CDKL5,15q Duplication Syndrome, KCNQ2 related epileptic encephalopathy, SCN8A related epileptic encephalopathy, Electrical status epilepticus in sleep (ESES), Landau-Kleffner syndrome, Continuous spikes and waves during sleep, Tuberous sclerosis complex, Doose Syndrome, Otahara Syndrome, Rett Syndrome, West Syndrome, SYNGAP related epileptic encephalopathy, Fragile X Syndrome, epilepsy with focal cortical dysplasia type II, KCNT1 related epileptic encephalopathy, SCN2A related epileptic encephalopathy, STXBP1 related epileptic encephalopathy, KAND KIF1A related epileptic encephalopathy, HNRNPH2 related epileptic encephalopathy, Phelan-McDermid Syndrome - SHANK3, Angelman Syndrome, Established Status Epilepticus, Refractory Status Epilepticus, Juvenile Myoclonic Epilepsy/Janz Syndrome, Catamenial epilepsy, Drug resistant mesial temporal lobe epilepsy, Occipital Lobe epilepsy, Jeavons syndrome, Benign Rolandic epilepsy or benign childhood epilepsy with centrotemporal spikes (BCECTS), Epilepsy with myoclonic absences, Childhood absence epilepsy (CAE), Tuberous Sclerosis/Tuberous Sclerosis Complex (TSC), Panayiotopoulos syndrome, Benign Occipital Epilepsy, Idiopathic childhood occipital epilepsy of Gastaut (ICOE-G), Benign myoclonic epilepsy in infancy, Myoclonic astatic epilepsy (MAE), Cornelia de Lange Syndrome (CdLS), Convulsive Seizures, TBI Seizures, Focal Seizures, Generalized onset Seizures, Progressive Myoclonic Epilepsy, Reflex Epilepsy, Abdominal Epilepsy, Photosensitive Epilepsy, Refractory Epilepsy, Automatism Epilepsy, Catamenial epilepsy, Epilepsia partialis continua, Febrile infection-related epilepsy syndrome (FIRES), Migralepsy, Musicogenic epilepsy, Nocturnal Frontal Lobe epilepsy, Occipital Lobe epilepsy, Post-traumatic (TBI) epilepsy (PTE), Temporal lobe epilepsy (TLE), Unverricht-Lundborg disease (abbreviated ULD or EPM1), Vertiginous epilepsy; suppositories infused with cannabis, medical marijuana, natural cannabinoids, cannabis derivatives, or synthetic cannabinoids; Suppositories infused with cannabis, medical marijuana, cannabis derivatives, natural cannabinoids, or synthetic cannabinoids for treating headaches, neurodegeneration, neurogenesis, epilepsy, childhood epilepsy, paediatric encephalopathies, pain, cancer, managing the effects of chemotherapy, Tourette Syndrome, post-traumatic stress disorder (PTSD), nausea, vomiting, premenstrual syndrome (PMS), neurologic conditions, sleep disorders, cognitive decline, facial pain, spasms, gastrointestinal diseases, rare diseases, Alzheimer's disease, appetite loss, cancer, Crohn's disease, anorexia, bulimia, epilepsy, glaucoma, schizophrenia, multiple sclerosis, muscle spasms, nausea, pain, headaches, wasting syndrome (cachexia), and diseases classified as "orphan" by the US Food and Drug Administration, namely, Lennox-Gastaut Syndrome, Dravet Syndrome, CDKL5,15q Duplication Syndrome, KCNQ2 related epileptic encephalopathy, SCN8A related epileptic encephalopathy, Electrical status epilepticus in sleep (ESES), Landau-Kleffner syndrome, Continuous spikes and waves during sleep, Tuberous sclerosis complex, Doose Syndrome, Otahara Syndrome, Rett Syndrome, West Syndrome, SYNGAP related epileptic encephalopathy, Fragile X Syndrome, epilepsy with focal cortical dysplasia type II, KCNT1 related epileptic encephalopathy, SCN2A related epileptic encephalopathy, STXBP1 related epileptic encephalopathy, KAND KIF1A related epileptic encephalopathy, HNRNPH2 related epileptic encephalopathy, Phelan-McDermid Syndrome - SHANK3, Angelman Syndrome, Established Status Epilepticus, Refractory Status Epilepticus, Juvenile Myoclonic Epilepsy/Janz Syndrome, Catamenial epilepsy, Drug resistant mesial temporal lobe epilepsy, Occipital Lobe epilepsy, Jeavons syndrome, Benign Rolandic epilepsy or benign childhood epilepsy with centrotemporal spikes (BCECTS), Epilepsy with myoclonic absences, Childhood absence epilepsy (CAE), Tuberous Sclerosis/Tuberous Sclerosis Complex (TSC), Panayiotopoulos syndrome, Benign Occipital Epilepsy, Idiopathic childhood occipital epilepsy of Gastaut (ICOE-G), Benign myoclonic epilepsy in infancy, Myoclonic astatic epilepsy (MAE), Cornelia de Lange Syndrome (CdLS), Convulsive Seizures, TBI Seizures, Focal Seizures, Generalized onset Seizures, Progressive Myoclonic Epilepsy, Reflex Epilepsy, Abdominal Epilepsy, Photosensitive Epilepsy, Refractory Epilepsy, Automatism Epilepsy, Catamenial epilepsy, Epilepsia partialis continua, Febrile infection-related epilepsy syndrome (FIRES), Migralepsy, Musicogenic epilepsy, Nocturnal Frontal Lobe epilepsy, Occipital Lobe epilepsy, Post-traumatic (TBI) epilepsy (PTE), Temporal lobe epilepsy (TLE), Unverricht-Lundborg disease (abbreviated ULD or EPM1), Vertiginous epilepsy; transdermal patches infused with cannabis, medical marijuana, marijuana plant derivatives, natural cannabinoids, or synthetic cannabinoids; Transdermal patches infused with cannabis, medical marijuana, marijuana plant derivatives, natural cannabinoids, or synthetic cannabinoids for treating headaches, neurodegeneration, neurogenesis, epilepsy, childhood epilepsy, paediatric encephalopathies, pain, cancer, managing the effects of chemotherapy, Tourette Syndrome, post-traumatic stress disorder (PTSD), nausea, vomiting, premenstrual syndrome (PMS), neurologic conditions, sleep disorders, cognitive decline, facial pain, spasms, gastrointestinal diseases, rare diseases, Alzheimer's disease, appetite loss, cancer, Crohn's disease, anorexia, bulimia, epilepsy, glaucoma, schizophrenia, multiple sclerosis, muscle spasms, nausea, pain, headaches, wasting syndrome (cachexia), and diseases classified as "orphan" by the US Food and Drug Administration, namely, Lennox-Gastaut Syndrome, Dravet Syndrome, CDKL5,15q Duplication Syndrome, KCNQ2 related epileptic encephalopathy, SCN8A related epileptic encephalopathy, Electrical status epilepticus in sleep (ESES), Landau-Kleffner syndrome, Continuous spikes and waves during sleep, Tuberous sclerosis complex, Doose Syndrome, Otahara Syndrome, Rett Syndrome, West Syndrome, SYNGAP related epileptic encephalopathy, Fragile X Syndrome, epilepsy with focal cortical dysplasia type II, KCNT1 related epileptic encephalopathy, SCN2A related epileptic encephalopathy, STXBP1 related epileptic encephalopathy, KAND KIF1A related epileptic encephalopathy, HNRNPH2 related epileptic encephalopathy, Phelan-McDermid Syndrome - SHANK3, Angelman Syndrome, Established Status Epilepticus, Refractory Status Epilepticus, Juvenile Myoclonic Epilepsy/Janz Syndrome, Catamenial epilepsy, Drug resistant mesial temporal lobe epilepsy, Occipital Lobe epilepsy, Jeavons syndrome, Benign Rolandic epilepsy or benign childhood epilepsy with centrotemporal spikes (BCECTS), Epilepsy with myoclonic absences, Childhood absence epilepsy (CAE), Tuberous Sclerosis/Tuberous Sclerosis Complex (TSC), Panayiotopoulos syndrome, Benign Occipital Epilepsy, Idiopathic childhood occipital epilepsy of Gastaut (ICOE-G), Benign myoclonic epilepsy in infancy, Myoclonic astatic epilepsy (MAE), Cornelia de Lange Syndrome (CdLS), Convulsive Seizures, TBI Seizures, Focal Seizures, Generalized onset Seizures, Progressive Myoclonic Epilepsy, Reflex Epilepsy, Abdominal Epilepsy, Photosensitive Epilepsy, Refractory Epilepsy, Automatism Epilepsy, Catamenial epilepsy, Epilepsia partialis continua, Febrile infection-related epilepsy syndrome (FIRES), Migralepsy, Musicogenic epilepsy, Nocturnal Frontal Lobe epilepsy, Occipital Lobe epilepsy, Post-traumatic (TBI) epilepsy (PTE), Temporal lobe epilepsy (TLE), Unverricht-Lundborg disease (abbreviated ULD or EPM1), Vertiginous epilepsy; Cannabis, cannabinoids, and medical marijuana based petfoods and medications; Cannabis, cannabinoids, and medical marijuana based pet foods and medications for treating pets for veterinary conditions; edible oils and edible butters containing cannabis, medical marijuana, marijuana plant derivatives, natural cannabinoids, or synthetic cannabinoids; Edible oils and edible butters containing cannabis, medical marijuana plant derivatives, natural cannabinoids, or synthetic cannabinoids for treating headaches, neurodegeneration, neurogenesis, epilepsy, childhood epilepsy, paediatric encephalopathies, pain, cancer, managing the effects of chemotherapy, Tourette Syndrome, post-traumatic stress disorder (PTSD), nausea, vomiting, premenstrual syndrome (PMS), neurologic conditions, sleep disorders, cognitive decline, facial pain, spasms, gastrointestinal diseases, rare diseases, Alzheimer's disease, appetite loss, cancer, Crohn's disease, anorexia, bulimia, epilepsy, glaucoma, schizophrenia, multiple sclerosis, muscle spasms, nausea, pain, headaches, wasting syndrome (cachexia), and diseases classified as "orphan" by the US Food and Drug Administration, namely, Lennox-Gastaut Syndrome, Dravet Syndrome, CDKL5,15q Duplication Syndrome, KCNQ2 related epileptic encephalopathy, SCN8A related epileptic encephalopathy, Electrical status epilepticus in sleep (ESES), Landau-Kleffner syndrome, Continuous spikes and waves during sleep, Tuberous sclerosis complex, Doose Syndrome, Otahara Syndrome, Rett Syndrome, West Syndrome, SYNGAP related epileptic encephalopathy, Fragile X Syndrome, epilepsy with focal cortical dysplasia type II, KCNT1 related epileptic encephalopathy, SCN2A related epileptic encephalopathy, STXBP1 related epileptic encephalopathy, KAND KIF1A related epileptic encephalopathy, HNRNPH2 related epileptic encephalopathy, Phelan-McDermid Syndrome - SHANK3, Angelman Syndrome, Established Status Epilepticus, Refractory Status Epilepticus, Juvenile Myoclonic Epilepsy/Janz Syndrome, Catamenial epilepsy, Drug resistant mesial temporal lobe epilepsy, Occipital Lobe epilepsy, Jeavons syndrome, Benign Rolandic epilepsy or benign childhood epilepsy with centrotemporal spikes (BCECTS), Epilepsy with myoclonic absences, Childhood absence epilepsy (CAE), Tuberous Sclerosis/Tuberous Sclerosis Complex (TSC), Panayiotopoulos syndrome, Benign Occipital Epilepsy, Idiopathic childhood occipital epilepsy of Gastaut (ICOE-G), Benign myoclonic epilepsy in infancy, Myoclonic astatic epilepsy (MAE), Cornelia de Lange Syndrome (CdLS), Convulsive Seizures, TBI Seizures, Focal Seizures, Generalized onset Seizures, Progressive Myoclonic Epilepsy, Reflex Epilepsy, Abdominal Epilepsy, Photosensitive Epilepsy, Refractory Epilepsy, Automatism Epilepsy, Catamenial epilepsy, Epilepsia partialis continua, Febrile infection-related epilepsy syndrome (FIRES), Migralepsy, Musicogenic epilepsy, Nocturnal Frontal Lobe epilepsy, Occipital Lobe epilepsy, Post-traumatic (TBI) epilepsy (PTE), Temporal lobe epilepsy (TLE), Unverricht-Lundborg disease (abbreviated ULD or EPM1), Vertiginous epilepsy; Cannabis, medical marijuana, marijuana plant derivatives, natural cannabinoids, or synthetic cannabinoids - infused foods for medical purposes, namely, frozen foods, treats, desserts, baked goods, desserts, grain based bars, cakes, cereal bars, cookies, brownies, muffins, cupcakes, chocolate, chocolate confectionery, sugar confectionery, candies, gum, jellies, biscuits, ice cream, sorbet, and frozen bars; beverages infused with medical cannabis, medical marijuana, medical marijuana plant derivatives, medical natural cannabinoids, or medical synthetic cannabinoids
35 Providing information to the public in the field of medical cannabis and its use in the treatment of medical conditions
40 Manufacturing medical cannabis compounds to the order and specification of others; manufacturing products that contain medical cannabis compounds to the order and specification of others
42 Research, development and formulation services in the field of medical cannabis compounds to the order and specification of others; research, development and formulation services in the field of products that contain medical cannabis compounds to the order and specification of others; providing information to the public in the field of research in the field of medical marijuana
44 Providing information to the public via an Internet website in the field of pharmaceutical advice concerning medical cannabis and its use in the treatment of medical conditions

Trademark history

Date Document number Area Entry
June 8, 2023 2023/23 Gaz JP Rejection
January 24, 2023 2023/4 Gaz AU RAW: Rule 18ter(2)(ii) GP following a provisional refusal
September 9, 2022 2022/38 Gaz EM Rejection
August 2, 2022 2022/32 Gaz AU Rejection
September 13, 2021 CA Registration

ID: 141674567

We use cookies to store your preferences and statistics and to improve our content. By clicking "Accept All" you accept the use of cookies.

Accept